Generic Product Showcase-December 2014

Generic SupplementsGeneric Supplement 2014

ATOVAQUONE ORAL SUSPENSION, USPMarketed by: Amneal Pharmaceuticals

Compare to: Mepron Oral Suspension (GlaxoSmithKline)

Indication: Amneal Pharmaceuticals has launched atovaquone oral suspension USP, a first-to-market generic medication that is an AB-rated therapeutic equivalent of GlaxoSmithKline's Mepron Oral Suspension. Atovaquone oral suspension USP is available in 750 mg/5 mL strength, and comes packaged in 210-mL (8 fl oz) bottles. It is indicated for the prevention of Pneumocystis jiroveci pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole. It is also indicated for the acute oral treatment of mild to moderate Pneumocystis pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.

Dosage Form: Oral suspension: 750 mg/5 mL

For More Information:

Marketed by: Mylan, Inc.

Compare to: Combivir (Viiv Healthcare)

Indication: Mylan, Inc, has announced the launch of its lamivudine and zidovudine tablets, USP, 150 mg/300 mg, which is the generic version of Viiv Healthcare's Combivir. Mylan received final approval from the FDA of its Abbreviated New Drug Application for this product, which is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. Mylan has begun shipping this product.

Dosage Form: Tablets: 150 mg/300 mg

For More Information:


Marketed by: Amneal Pharmaceuticals

Compare to: Cleocin Pediatric (Pharmacia and Upjohn)

Indication: Amneal Pharmaceuticals announced the launch of clindamycin palmitate hydrochloride for oral solution USP (pediatric), which is available in 75 mg/5 mL reconstituted strength. The Amneal product is an AA-rated therapeutic equivalent to Pharmacia and Upjohn’s Cleocin Pediatric. Mixing the powder with water provides 100 mL of a clear, cherry-flavored solution. It is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria.

Dosage Form: Oral solution: 75 mL/5 mg


Compare to: Focalin XR Extended- Release Capsules (Novartis AG Corp)

Indication: Teva Pharmaceuticals announced the introduction and availability of dexmethylphenidate hydrochloride extended-released capsules, CII, in a 5-mg strength. The product is AB rated and is bioequivalent to Focalin XR Extended-Release Capsules, CII. With the addition of this new strength, Teva now offers Dexmethylphenidate HCL ER Capsules in 5-mg, 15-mg, 30-mg, and 40-mg strengths.

Dosage Form: Capsules: 5 mg

For More Information:

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.